Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

RAD Launching American Depositary Receipt (ADR) Program

Thursday, September 19, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has announced the launch of its American Depositary Receipt (ADR) program, which is expected to enhance its visibility in the U.S. market. This initiative comes alongside positive updates from its clinical programs, including the recent IND approval from the FDA for a Phase I therapeutic study targeting B7H3 with Betabart (RV-01).

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of American Depositary Receipt (ADR) program
  • Positive clinical updates across multiple programs
  • IND approval from US FDA for Phase I study

Full Press Release Details

• Announcements
• September 19, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• October 22, 2022
• Announcements
• January 24, 2024
• Announcements
• December 9, 2022
• Announcements
• June 25, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the purpose of RAD's ADR program?

The ADR program aims to enhance Radiopharm Theranostics' visibility in the U.S. market.

What recent FDA approval did Radiopharm receive?

Radiopharm received IND approval from the FDA to initiate a Phase I study targeting B7H3.

What is Betabart (RV-01)?

Betabart (RV-01) is a therapeutic agent being studied in Radiopharm's clinical trials.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics ADR program FDA approval Phase I study Betabart
Last updated: Sep 19, 2024